Aradigm Corporation, a specialty pharmaceutical company, focuses on developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Its activities primarily include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary hypertension, asthma and bronchitis, inhalation anthrax infections, and smoking cessation. The company also develops AERx insulin diabetes management system (iDMS), which is in Phase III clinical trials for the treatment of Type I and Type II diabetes. Its proprietary product candidates under development include ARD-3100 under Phase II clinical trial for the treatment of cystic fibrosis; ARD-3150 for the treatment of bronchiectasis and ARD-1600 for the treatment of tobacco smoking cessation, which are under Phase I clinical trial; and ARD-1100, a preclinical product for the treatment of inhalation anthrax indications. The company’s collaborative product candidates comprise ARD-1550 and ARD-1500 for the treatment of pulmonary arterial hypertension, and ARD-1700 for the treatment of asthma and chronic obstructive pulmonary disease, which are under preclinical trial; and ARD-1300, a Phase II clinical trial product for the treatment of asthma. Aradigm Corporation has a collaboration agreement with CyDex Pharmaceuticals, Inc. for the development and commercialization of combination products containing inhaled corticosteroids, anticholinergics, and beta-2 agonists for the treatment of asthma and chronic obstructive pulmonary diseases. It also has collaborations with Lung Rx, Inc.; GlaxoSmithKline; and APT Pharmaceuticals, Inc.
ARDM at 9:45 AM 10/15/2008: Improving Chaikin Money Flow
